Business Description
Adicet Bio Inc
NAICS : 541714
SIC : 2834
ISIN : US0070021086
Share Class Description:
FRA:1IJ: Ordinary SharesTotal Employee Number:
102Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.9 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.1 | |||||
3-Year EPS without NRI Growth Rate | 14.6 | |||||
3-Year FCF Growth Rate | 16.3 | |||||
3-Year Book Growth Rate | -46.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.53 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.95 | |||||
9-Day RSI | 69.39 | |||||
14-Day RSI | 64.85 | |||||
3-1 Month Momentum % | 16.13 | |||||
6-1 Month Momentum % | 6.19 | |||||
12-1 Month Momentum % | -26.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.65 | |||||
Quick Ratio | 7.65 | |||||
Cash Ratio | 7.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.8 | |||||
Shareholder Yield % | 3.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -77.38 | |||||
ROA % | -63.54 | |||||
ROIC % | -273.21 | |||||
3-Year ROIIC % | 131.82 | |||||
ROC (Joel Greenblatt) % | -356.84 | |||||
ROCE % | -71.17 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.35 | |||||
EV-to-EBITDA | 0.37 | |||||
EV-to-Forward-Revenue | 13.42 | |||||
EV-to-FCF | 0.42 | |||||
Price-to-GF-Value | 19.53 | |||||
| Price-to-Net-Current-Asset-Value | 0.79 | |||||
| Price-to-Net-Cash | 0.81 | |||||
Earnings Yield (Greenblatt) % | 285.71 | |||||
FCF Yield % | -107.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adicet Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -12.806 | ||
| Beta | 2.589 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.6 | ||
| Volatility % | 52.5 | ||
| 14-Day RSI | 64.85 | ||
| 14-Day ATR (€) | 0.371741 | ||
| 20-Day SMA (€) | 7.295 | ||
| 12-1 Month Momentum % | -26.53 | ||
| 52-Week Range (€) | 5.05 - 15 | ||
| Shares Outstanding (Mil) | 9.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adicet Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adicet Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 94 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 10:30 | In 9 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 4 days | ||
| General meeting for 2026 | 2026-06-17 17:00 | 6.70 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 07:35 | 6.60 (-0.75%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 6.65 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 6.10 (-0.81%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 6.10 (-0.81%) | ||
| Guidance call for 2026 | 2026-02-12 14:00 | 5.70 (+0.00%) | ||
| 0.0625:1 Stock Split | 2025-12-30 | 6.27 (+0.00%) |
Show
Entries
Adicet Bio Inc Frequently Asked Questions
What is Adicet Bio Inc(FRA:1IJ)'s stock price today?
The current price of FRA:1IJ is €8.40. The 52 week high of FRA:1IJ is €15.00 and 52 week low is €5.05.
When is next earnings date of Adicet Bio Inc(FRA:1IJ)?
The next earnings date of Adicet Bio Inc(FRA:1IJ) is 2026-08-07 Est..
Does Adicet Bio Inc(FRA:1IJ) pay dividends? If so, how much?
Adicet Bio Inc(FRA:1IJ) does not pay dividend.
Press Release
Articles on Adicet Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers